Valsartan pregnancy category

Valsartan, like other medications in the angiotensin II receptor blocker (ARB) class, is generally not recommended for use during pregnancy due to potential risks to the developing fetus. The use of ARBs during pregnancy, including valsartan, has been associated with adverse outcomes, particularly during the second and third trimesters.

Pregnancy     Category D       ( by FDA )

                       Category  D       (AU TGA )

Exposure to ARBs in pregnancy may lead to fetal harm, including reduced kidney function, low amniotic fluid levels, developmental abnormalities, and even fetal death. Therefore, it's crucial for pregnant women or those planning pregnancy to avoid taking valsartan and other ARB medications unless specifically directed by their healthcare provider.